ArticleImmunity2020
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 249 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
249citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
249 citing papers in PubMed, 1 synthesis or guideline pooled it, 380 citations in OpenAlex.
- A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.Human vaccines & immunotherapeutics · 2022Pooled it
- The mRNA-based RSV vaccine mRNA-1345 induces robust and durable CD4Science advances · 2026Article
- Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms.Cells · 2026Review
- Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.Nature biomedical engineering · 2026Article
- Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.Nature communications · 2026Article
- BPTF is essential for vaccine-induced germinal center B cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Development and protective evaluation of mRNA vaccines encoding the glycoprotein precursor of lymphocytic choriomeningitis virus.Virus research · 2026Article
- Review
- Article
- Article
- A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions.NPJ vaccines · 2026Article
- Comparison of Vaccine Platforms for Machupo Virus.Vaccines · 2026Article
- One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development.Science advances · 2026Article
- Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- Comparison of Immune Cell Transfection by Different Vaccine Vectors After Intradermal Injection.Vaccines · 2026Article
- Nucleocapsid protein enhances spike- and RBD-specific humoral and cellular immune responses in protein-based SARS-CoV-2 vaccine.BMC infectious diseases · 2026Article
- An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial.NPJ vaccines · 2026Article
- Working towards a single-dose vaccine for rabies post-exposure prophylaxis.Future virology · 2026Article
- Article
189 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 10 institutions in 4 countries.
Dorottya LaczkóDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael J HoganDivision of Protective Immunity, Children's Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Sushila A ToulminDivision of Protective Immunity, Children's Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Philip HicksDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Katlyn LedererDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Brian T GaudetteThe Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Diana CastañoDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Grupo de Inmunología Celular e Inmunogenética, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hiromi MuramatsuDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Thomas H OguinDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Amrita OjhaDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Lizhou ZhangDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Zekun MuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Tomaz B ManzoniDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Brianne RoperDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shirin StrohmeierDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
István TombáczDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Leslee ArwoodDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Raffael NachbagauerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Katalin KarikóDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA; BioNTech RNA Pharmaceuticals, Mainz, Germany.
Jack GreenhouseBIOQUAL Inc., Rockville, MD, USA.
Laurent PessaintBIOQUAL Inc., Rockville, MD, USA.
Maciel PortoBIOQUAL Inc., Rockville, MD, USA.
Tammy Putman-TaylorBIOQUAL Inc., Rockville, MD, USA.
Amanda StrasbaughBIOQUAL Inc., Rockville, MD, USA.
Tracey-Ann CampbellBIOQUAL Inc., Rockville, MD, USA.
Paulo J C LinAcuitas Therapeutics, Vancouver, BC, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, BC, Canada.
Gregory D SempowskiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Michael FarzanDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Hyeryun ChoeDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Hanne AndersenBIOQUAL Inc., Rockville, MD, USA.
Laurence C EisenlohrDivision of Protective Immunity, Children's Hospital of the University of Pennsylvania, Philadelphia, PA, USA; The Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Paul BatesDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David AllmanThe Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Michela LocciDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Norbert PardiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: pnorbert@pennmedicine.upenn.edu.
University of Pennsylvania · USBioqual · USDuke University · USIcahn School of Medicine at Mount Sinai · USScripps Research Institute · USChildren's Hospital of Philadelphia · USAcuitas Therapeutics (Canada) · CABioNTech (Germany) · DEPenn Center for AIDS Research · USUniversidad de Antioquia · CO
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MProject 2 - GMP Manufacturing of mRNA ImmunogensU19AI142596 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2024
$19.0MRegional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MTRAINING IN VIROLOGYT32AI007324 · NIAID · WISTAR INSTITUTE · PI Paul Bates, Matthew D. Weitzman · 1989 to 2026
$6.8MOptimizing eCD4-Ig for eradication and a functional cureR01AI129868 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2017 to 2021
$5.2MPARASITOLOGY: MODERN APPROACHEST32AI007532 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HERBERT, DE'BROSKI R · 1998 to 2022
$5.0MTraining in Emerging Infectious DiseasesT32AI055400 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, HENSLEY, SCOTT ERIC · 2003 to 2022
$4.4MVMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5MNucleoside modified mRNA based HIV vaccineR01AI124429 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2016 to 2019
$3.4MDevelopment of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNAR01AI146101 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PARDI, NORBERT · 2019 to 2023
$3.1MDevelopment of vaccines targeting a tick-borne phlebovirusR01AI152236 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BATES, PAUL · 2020 to 2024
$3.0MNCI NIH HHS T32 CA009140NHLBI NIH HHS F30 HL145907NIAID NIH HHS 75N93019C00051NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI123738NIAID NIH HHS R01 AI124429NIAID NIH HHS R01 AI129868NIAID NIH HHS R01 AI146101NIAID NIH HHS R01 AI152236NIAID NIH HHS R21 AI129531NIAID NIH HHS R21 AI142638NIAID NIH HHS T32 AI007324NIAID NIH HHS T32 AI007532NIAID NIH HHS T32 AI055400NIAID NIH HHS T32 AI070077NIAID NIH HHS U19 AI142596NIAID NIH HHS UC6 AI058607
Abstract
SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCoronavirus InfectionsCOVID-19COVID-19 VaccinesDisease Models, AnimalFurinHumansImmunity, HumoralImmunizationImmunogenicity, VaccineAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesFurinRNA, MessengerRNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticViral VaccinesCOVID-19mRNA-LNPmRNA vaccinenucleoside-modified mRNASARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.